Advanced Enzyme Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹215 Cr +16.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AE

Advanced Enzyme Technologies Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹172Cr
+1.8% YoY
−7% QoQ
Net profit
₹43Cr
+10.3% YoY
−4.4% QoQ
Margin
29%
−4 pp YoY
−4 pp QoQ
Price₹300
Market cap₹3.7K Cr
P/E24.0

The short version

The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.

From Advanced Enzyme Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22).
  • Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22).
  • There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24).
  • Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19).
  • The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17).

2 more points from Advanced Enzyme Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No major CapEx planned for the current fiscal year except for R&D-related investments.
  • Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year.
  • Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation.
  • Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion.

2 more points from Advanced Enzyme Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year.
  • The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes.
  • There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders.

2 more points from Advanced Enzyme Technologies Ltd's call on order book

Create a free account to keep reading this call

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Advanced Enzyme Technologies Ltd Q3 FY26 results — key figures

Advanced Enzyme Technologies Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue172169+1.8%185-7%
Operating profit (EBITDA)4955-10.9%60-18.3%
Operating margin29%33%-4 pp33%-4 pp
Profit before tax5853+9.4%60-3.3%
Net profit (PAT)4339+10.3%45-4.4%
EPS (₹)3.803.37+12.8%3.87-1.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q3 FY26 results?

The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). - Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). - There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). - Stronger inquiries and interest are seen particularly in the U.S. The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

No major CapEx planned for the current fiscal year except for R&D-related investments.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.